Technology Breakthroughs Driving Allergy & Infectious Disease Therapy
Forthcoming and Available Therapies for Allergy, Infectious Diseases and COVID-19
29-Apr-2020
Global
Technology Research
D98F-01-00-00-00
HC03291-GL-TR_24371
The current research study discusses the available countermeasures and forthcoming allergic and infectious diseases. The most common allergic diseases such as allergic rhinitis, also know as Hay fever or seasonal allergies; sinusitis; asthma and chronic obstructive pulmonary disease (COPD); atopic dermatitis (or eczema); urticaria (or hives) and most severe allergic reaction anaphylaxis are covered under allergic diseases. This study looks at the first-line therapies available such as antihistamine, topical and oral corticosteroids, leukotriene receptor antagonists, decongestants, topical calcineurin inhibitors, enzyme/kinase inhibitors, antimicrobials such as antifungals and antibiotics, steroids, immunosuppressants, epinephrine therapy, and other drugs and nonpharmacological interventions. This research service also talks about immunotherapies in allergic diseases such as monoclonal antibodies (mAbs) directed toward interleukin (IL): Mepolizumab, Reslizumab, Benralizumab, anti-immunoglobin E (anti-Ig-E) mAb: Omalizumab; future therapeutic targets, desensitisation, and possible surgeries.
For infectious disease, this research study covers World Health Organization (WHO)’s eleven priority diseases, which include Crimean-Congo haemorrhagic fever, Ebola virus disease and Marburg virus disease, Lassa fever, Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS), Nipah and henipaviral diseases, Rift Valley fever, Zika and recently added COVID-19. On a broader lever, this study delineates anti-virals (favipiravir, Remdesivir ribavirin, lopinavir), repurposed and repositioned drugs (hydroxy-chloroquine, chloroquine, interferon-beta), biologics such as vaccines including mRNA vaccines, mAbs, novel recombinant protein therapeutics, first commercialized ebola vaccine, natural medicines, cell therapies, and most recent clinical updates.
A major section of this study deals with potential therapeutics, drug discovery attempts, vaccines and biologics for human corona viruses, SARS-CoV, MERS-CoV, and novel corona virus 2019-nCoV (also known as SARS-CoV, responsible for COVID-19) and their clinical trials, sponsors, and collaborators. Selected drugs and company profiles are presented at the end of this study.
1.1 Research Scope: Therapies for Most Common Allergic, Infectious Diseases Including COVID-19
1.2 Analysis Framework: Frost & Sullivan Core Value
1.3 Research Methodology: Five Steps Toward Success
1.4 Key Findings of Technology Breakthrough Driving Allergy & Infectious Disease Therapies
2.1 Research Scope: Current Status and Challenges of Allergic and Infectious Diseases
2.2 List of Diseases Discussed in this Research Study
3.1 Most Common Allergic Diseases
3.2 First-line Therapy of Allergic Rhinitis – Antihistamines
3.3 First-line Therapy of Allergic Rhinitis – Other Therapies
3.4 Novel Therapies for Asthma and COPD
3.5 Future Targets and Therapies for Asthma and COPD
3.6 Nonpharmacological Therapy for Atopic Dermatitis
3.7 Pharmacological Treatments of Atopic Dermatitis
3.8 Systemic Therapy for Atopic Dermatitis
3.9 Current and Upcoming Treatments for Sinusitis
3.10 Treatment of Urticaria
3.11 First-line Treatment of Anaphylaxis
3.12 Treatment and Management of Anaphylaxis Through Desensitization
4.1 WHO’s Priority Diseases for R&D in Public Health Emergency
4.2 Treatment of Crimean-Congo Hemorrhagic Fever
4.3 Clinical Trials of Crimean-Congo Hemorrhagic Fever
4.4 First Ebola Virus Vaccine Was Approved by the US FDA in 2019
4.5 Phase 3 and Phase 4 Clinical Trials for Ebola Virus Disease
4.6 Outlook of Treatments for Marburg Virus Infection
4.7 Active Clinical Trials for Marburg Virus Infection
4.8 Upcoming Treatments of Lassa Fever
4.9 Developments in Zika Virus Infection Therapeutics
4.10 Clinical Trials for Interventions of Zika Virus Infections
4.11 Novel System to Reduce the Risk of Transfusion-transmitted Infections
4.12 Prevention and Control of Rift Valley Fever Virus Infection
4.13 Clinical Trials for Rift Valley Fever Virus Infection
4.14 Viruses of the Genus Henipavirus: Nipah & Hendra Virus
4.15 Clinical Trials for Nipah Virus
5. 1 Human Coronaviruses and Their Properties
5.2 BatCoVs and Intermediate Hosts: Reservoirs for Emerging Human CoVs
5.3 Outlook of MERS-CoV Clinical Trials
5.4 Outlook of SARS-CoV and SARS-CoV-2 Clinical Trials
5.5 Repurposed Drugs: Potential Anti-COVID-19 Therapies
5.6 Phase 3 Interventions for SARS-CoV/SARS-CoV2
5.7 Antiviral and Antimalarial Interventions for SARS-CoV/SARS-CoV-2 in Phase 3 Clinical Trials
5.8 Other Phase 3 Interventions for SARS-CoV/SARS-CoV-2
5.9 Phase 4 Clinical Trials for COVID-19
5.10 Currently Used Compounds for Treatment of COVID-19
5.11 Emerging COVID-19 Therapies
5.12 Potential Lentivirus-based Minigene SARS-CoV-2 Vaccines
5.13 Potential Adenovirus and mRNA-based COVID-19 Vaccines
5.14 Clinical Trials of Potential Cell Therapies for COVID-19
5.15 Major Participants in Anti-COVID-19 Drug Discovery
5.16 Innovators Fuelling Anti-COVID-19 Drug Discovery
5.17 Industry Participants Enabling Anti-COVID-19 Drug Discovery
5.18 Novel Biologic Drug for Sialic Acid Dependent Viruses
6.1 Growth Opportunity 1: Personized Therapies for Allergic Diseases
6.2 Growth Opportunity 2: Potential Novel Therapeutics for COVID-19
7.1 Industry Interactions
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
19 Nov 2026 | Global | Technology Research
Programmable Vaccines: AI-Designed Antigens and Next-Generation Rapid Platforms
Traditional vaccine development is an empirical, time-consuming process that often leads to a high failure rate. With the proven clinical success of RNA vaccines, there has been a focus on accelerating the development of vaccines to address the growing incidence of infectious diseases and emerging p...
17 Nov 2026 | Global | Frost Radar
Frost Radar™: Quantum-Grade Sensor Technology Ecosystem for Healthcare Applications, 2026
Quantum-grade sensors are advancing healthcare by leveraging quantum phenomena to enable highly sensitive, precise, and non-invasive measurements of biological signals and physiological parameters. These innovations enhance diagnostic accuracy, disease monitoring, brain activity measurement, and ear...
16 Nov 2026 | North America | Frost Radar
Frost Radar™: Healthcare Data Interoperability Platforms and Integration Engines in North America, 2026
This Frost Radar™ analyzes the healthcare data platform and integration engine vendors that enable healthcare organization to improve the exchange, utilization, contextualization, and management of clinical, operational, financial, and administrative data. Data issues, AI adoption, and solution gove...
03 Nov 2026 | North America | Market Research
Enterprise Imaging Market, United States, 2025–2030
Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, ...
02 Nov 2026 | Global | Market Research
Continuous Glucose Monitoring Market, Global, 2026
The global continuous glucose monitoring (CGM) market is undergoing a fundamental transformation as the technology evolves from a prescription-led glucose monitoring device into an AI-connected metabolic intelligence ecosystem. Market expansion is increasingly driven by the emergence of over-the-cou...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.